ONESOURCEOnesource Specialty Pharma Limited
Pharma · Biotechnology · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Overall evidence is weak (AlgoScore 26/100)
- • Profit growth: -310.7% YoY
- • ROE: -1.3%
- • RSI: 39
- • MACD: bearish
⚖️ 1 bullish pattern setup is currently active on this stock. Pattern setup-quality percentages measure how cleanly a chart formation developed — they are not an endorsement of the company. Short-term traders may still trade those setups with strict stops; the AVOID verdict reflects the overall risk/fundamental profile for holding.
Bull case
- • Revenue growth: 37.2% YoY
- • Debt/Equity: 0.26
- • Trend strength (ADX): 29
- • Liquidity: ₹32.0 cr avg turnover
Bear case
- • Profit growth: -310.7% YoY
- • ROE: -1.3%
- • RSI: 39
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Profit growth: -310.7% YoY
- • ROE: -1.3%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹55.27). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.